Bayer: US Supreme Court ruling should result in dismissal of current warning-based claims
Bayer: US Supreme Court ruling should result in dismissal of current warning-based claims BERLIN, June 25 (Reuters) - A U.S. Supreme Court ruling that scales back Roundup cancer lawsuits and which sent Bayer shares up 18% should result in the dismissal of current warning-based claims and bar future failure-to-warn claims, the company said on Thursday.
"The U.S. Supreme Court decision is good for science, farmers, and industries that depend on regulatory clarity for innovation. It should help significantly contain the Roundup litigation after nearly a decade of legal battles," the company said in a statement.
(Writing by Madeline Chambers, Editing by Friederike Heine)
((Madeline.Chambers@thomsonreuters.com; +4930220133578;))
Recent news on Bayer AG
See all newsBrief: Bayer Says Finerenone Slowed Kidney Decline In CKD
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Deutsche Bank AG FF - Post Stabilisation Notice -Bayer EUR 30NC6 & 30NC9
Brief: Bayer To Present New Finerenone Data Across Chronic Kidney Disease With And Without Diabetes At Asn Kidney Week 2026
Brief: FDA Approves Once-Weekly Generic Hormone Therapy Patch For Women